NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2010.65 18.80 (0.94%)

34.64% Gain from 52W Low

304.8K NSE+BSE Volume

NSE 18 Mar, 2025 1:11 PM (IST)

91,794.4

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

US FDA Approval

Lupin gets US FDA tentative approval for Amifampridine tablets, with a market size of $306 million See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

09 Nov 2024

2010.65

0.94%

Lupin (BUY): In-line quarter; EBITDAM guidance increased to 25%

Buy: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

LPC's earnings were in line with our estimates but beat street's estimates. EBITDA margin was 23% in Q2FY25

Geojit BNP Paribas increased Hold price target of Lupin Ltd. to 2132.0 on 13 Mar, 2025.

Lupin Ltd.

08 Aug 2024

2010.65

0.94%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We have BUY on the Stock

Number of FII/FPI investors increased from 925 to 964 in Dec 2024 qtr.

Lupin Ltd.

08 Aug 2024

2010.65

0.94%

Strong products line up to support growth

Buy: Lupin Ltd.

Recommendation Target

KRChoksey

LUPIN witnessed a strong 16.3% Y-o-Y (+12.9% Q-o-Q) rise in reported revenue to INR 56,003 Mn (vs. our estimate of INR 57,525 Mn) in Q1FY25.
Adj. net income grew at 242.8% Y-o-Y (+49.4% Q-o-Q) to INR 8,509 Mn (vs. our estimate of INR 6,151 Mn, a beat of 31.0%) in Q1FY25.

Lupin Ltd. has an average target of 2329.44 from 9 brokers.

Lupin Ltd.

07 Aug 2024

2010.65

0.94%

Strong beat; US/India drive earnings

Neutral: Lupin Ltd.

Target

Motilal Oswal

LPC delivered a strong earnings beat in 1QFY25, led by a superior show in key markets (US/India), lower R&D spending and a low tax rate.

Lupin Ltd. has an average target of 2329.44 from 9 brokers.

Lupin Ltd.

07 Aug 2024

2010.65

0.94%

Strong Q1; complex products to drive growth

Buy: Lupin Ltd.

Target

Sharekhan

Q1FY2025 numbers were strong, beating our estimates on all fronts. Sales grew by 16% y-o-y to Rs. 5514 crore (9% above our estimates), on a 28% y-o-y growth in North America region to Rs. 2041 crore.

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

10 Jul 2024

2010.65

0.94%

Launches critical for sustenance of turnaround

Sell: Lupin Ltd.

Target

ICICI Securities Limited

Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio. Share of inhalation products has risen from 25% of US sales in FY22 (USD 185mn) to 40% in FY24
(USD 326mn) post the launch of gSpiriva. In India, growth had been subdued due to the discontinuation of in-licensed brands (contribution down from 15% in FY23 to 11% in Q4FY24).

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

15 May 2024

2010.65

0.94%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Geojit BNP Paribas increased Hold price target of Lupin Ltd. to 2132.0 on 13 Mar, 2025.

Lupin Ltd.

08 May 2024

2010.65

0.94%

Strong products line up to support growth

Accumulate: Lupin Ltd.

KRChoksey

Lupin reported a weaker quarterly revenue than expected. It reported 12.0% Y-o-Y (-4.6% Q-o-Q) rise in operating revenue to Rs. 49,608 Mn (estimated: Rs. 55,943 Mn) US market grew at 19.4% Y-o-Y (-1.4% Q-o-Q) to USD 209 Mn (estimated: USD 298 Mn), the third consecutive quarter of over USD 200 Mn revenue.